Logo image of MRNS

MARINUS PHARMACEUTICALS INC (MRNS) Stock Fundamental Analysis

NASDAQ:MRNS - Nasdaq - US56854Q2003 - Common Stock - Currency: USD

0.55  +0 (+0.09%)

Premarket: 0.5491 0 (-0.16%)

Fundamental Rating

2

Taking everything into account, MRNS scores 2 out of 10 in our fundamental rating. MRNS was compared to 197 industry peers in the Pharmaceuticals industry. MRNS has a bad profitability rating. Also its financial health evaluation is rather negative. MRNS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRNS had negative earnings in the past year.
In the past year MRNS has reported a negative cash flow from operations.
In the past 5 years MRNS always reported negative net income.
In the past 5 years MRNS always reported negative operating cash flow.
MRNS Yearly Net Income VS EBIT VS OCF VS FCFMRNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

MRNS's Return On Assets of -220.81% is on the low side compared to the rest of the industry. MRNS is outperformed by 90.81% of its industry peers.
Industry RankSector Rank
ROA -220.81%
ROE N/A
ROIC N/A
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
MRNS Yearly ROA, ROE, ROICMRNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

MRNS has a Gross Margin of 90.17%. This is amongst the best in the industry. MRNS outperforms 92.97% of its industry peers.
The Profit Margin and Operating Margin are not available for MRNS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRNS Yearly Profit, Operating, Gross MarginsMRNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

MRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNS has more shares outstanding
Compared to 5 years ago, MRNS has more shares outstanding
The debt/assets ratio for MRNS is higher compared to a year ago.
MRNS Yearly Shares OutstandingMRNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
MRNS Yearly Total Debt VS Total AssetsMRNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

MRNS has an Altman-Z score of -20.05. This is a bad value and indicates that MRNS is not financially healthy and even has some risk of bankruptcy.
MRNS has a worse Altman-Z score (-20.05) than 87.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.05
ROIC/WACCN/A
WACC11.46%
MRNS Yearly LT Debt VS Equity VS FCFMRNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.66 indicates that MRNS should not have too much problems paying its short term obligations.
MRNS's Current ratio of 1.66 is on the low side compared to the rest of the industry. MRNS is outperformed by 67.03% of its industry peers.
MRNS has a Quick Ratio of 1.47. This is a normal value and indicates that MRNS is financially healthy and should not expect problems in meeting its short term obligations.
MRNS has a Quick ratio of 1.47. This is in the lower half of the industry: MRNS underperforms 63.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.47
MRNS Yearly Current Assets VS Current LiabilitesMRNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.92% over the past year.
The Revenue has been growing slightly by 1.63% in the past year.
Measured over the past years, MRNS shows a very strong growth in Revenue. The Revenue has been growing by 162.16% on average per year.
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%

3.2 Future

Based on estimates for the next years, MRNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.60% on average per year.
The Revenue is expected to grow by 31.95% on average over the next years. This is a very strong growth
EPS Next Y19.91%
EPS Next 2Y34.46%
EPS Next 3Y23.56%
EPS Next 5Y15.6%
Revenue Next Year9.81%
Revenue Next 2Y31.57%
Revenue Next 3Y24.44%
Revenue Next 5Y31.95%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MRNS Yearly Revenue VS EstimatesMRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
MRNS Yearly EPS VS EstimatesMRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MRNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNS Price Earnings VS Forward Price EarningsMRNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNS Per share dataMRNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

MRNS's earnings are expected to grow with 23.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.46%
EPS Next 3Y23.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRNS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARINUS PHARMACEUTICALS INC

NASDAQ:MRNS (2/10/2025, 8:13:23 PM)

Premarket: 0.5491 0 (-0.16%)

0.55

+0 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-11 2025-03-11/amc
Inst Owners63.59%
Inst Owner Change-90.82%
Ins Owners0.32%
Ins Owner Change-21.99%
Market Cap30.37M
Analysts73.85
Price Target1.09 (98.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.15%
Min EPS beat(2)-0.53%
Max EPS beat(2)0.22%
EPS beat(4)1
Avg EPS beat(4)-4.39%
Min EPS beat(4)-16.47%
Max EPS beat(4)0.22%
EPS beat(8)4
Avg EPS beat(8)1.33%
EPS beat(12)6
Avg EPS beat(12)-24.79%
EPS beat(16)8
Avg EPS beat(16)-20.52%
Revenue beat(2)0
Avg Revenue beat(2)-13.95%
Min Revenue beat(2)-16.82%
Max Revenue beat(2)-11.09%
Revenue beat(4)0
Avg Revenue beat(4)-14.36%
Min Revenue beat(4)-17.5%
Max Revenue beat(4)-11.09%
Revenue beat(8)4
Avg Revenue beat(8)8.04%
Revenue beat(12)5
Avg Revenue beat(12)33.61%
Revenue beat(16)7
Avg Revenue beat(16)46.44%
PT rev (1m)-60.28%
PT rev (3m)-87.45%
EPS NQ rev (1m)-13.44%
EPS NQ rev (3m)37.61%
EPS NY rev (1m)-2.16%
EPS NY rev (3m)-6.38%
Revenue NQ rev (1m)1.09%
Revenue NQ rev (3m)-9.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0.57
BVpS-1.21
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -220.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.17%
FCFM N/A
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.53%
Cap/Sales 3.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.47
Altman-Z -20.05
F-Score2
WACC11.46%
ROIC/WACCN/A
Cap/Depr(3y)415.27%
Cap/Depr(5y)277.02%
Cap/Sales(3y)8.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
EPS Next Y19.91%
EPS Next 2Y34.46%
EPS Next 3Y23.56%
EPS Next 5Y15.6%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%
Revenue Next Year9.81%
Revenue Next 2Y31.57%
Revenue Next 3Y24.44%
Revenue Next 5Y31.95%
EBIT growth 1Y2.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.8%
OCF growth 3YN/A
OCF growth 5YN/A